Eli Lilly fell 0.2% in early Thursday trading. The company agreed to acquire Ventyx Biosciences in an all-cash deal to expand its line of oral small molecule therapies for chronic inflammation in multiple diseases.

Eli Lilly fell 0.2% in early Thursday trading. The company agreed to acquire Ventyx Biosciences in an all-cash deal to expand its line of oral small molecule therapies for chronic inflammation in multiple diseases.